fav link: web design

 

As the global population aging trend, the price of new drugs becoming more expensive, making increasingly heavy medical expenses, many governments have begun to actively encourage the use of generics. Although the United States through bilateral free trade agreements with TPP pushing patent link, limitations and quality regulatory risks and other factors, the global generics market is still showing steady growth momentum in the international community. TrendForce estimated 2016 global generics market size of up to about 3,149 one hundred million US dollars, in 2019 up to about 4,099 billion US dollars, 2015 - 2019 compound annual growth rate of about 8.7%.

 

The significance of the presence of generic drugs, is so that the public may be able to afford the price of access to medication therapy. TrendForce biotechnology analyst Liu Ning fitness noted steadily rising due to medical expenses, resulting in a heavy financial burden on States, many countries have resorted to incentives, it is intended to expand the penetration of generic drugs to reduce medical expenses. Such as the Japanese Ministry of Health 2020 target generic pharmaceutical market share of 80% of the amount, and actively approve generics market. France plans to implement cost control health spending, to be through lower drug prices and increased use of generic drugs, generic drugs reach the total pharmaceutical expenditure target of 25% in 2017.

 

Major pharmaceutical companies spotted the potential opportunities generics market, have sharpening. Because the United States is the largest pharmaceutical market, even if growth is slow, it has been still contested. Japan is pushing generics policies and high-profile, traditional patent brand pharmaceutical companies GlaxoSmithKline (GSK) and Sanofi (Sanofi) have been actively entered. Emerging market places, Mexico, Saudi Arabia, India and China generics market with the most potential for development.

 

Liu Ning said fitness, Taiwan pharmaceutical market is limited by the population and the national health insurance, resulting in small size and growth rate, such as pharmaceutical companies want to actively expand the scale of operation, can be taken to export or acquisition strategy. In the context of the development of the global pharmaceutical industry is concerned, only a few pharmaceutical companies can rely on a huge domestic market state of their own, to lay a solid foundation for multinational pharmaceutical companies, most pharmaceutical companies still export by the gradual growth and acquisitions, such as Israel, Pharmaceuticals Switzerland, Iceland, Ireland and other countries, can escape the limitations of the domestic market, the development of a large number of multinational pharmaceutical companies, which serves as the best example.